- Open Access
RNA interference as a gene silencing therapy for mutant MYOC protein in primary open angle glaucoma
Diagnostic Pathologyvolume 4, Article number: 46 (2009)
Primary open-angle glaucoma (POAG) is the most common form of glaucoma which is an irreversible blind leading disease and lacks effective remedies. In recent years, POAG has been linked to the gene MYOC encoding myocilin that has been identified to harbor causal mutations. A variety of studies show that the mutant myocilin acts by gain of function. The mutant MYOC protein induces endoplasmic reticulum (ER) stress and the resultant unfolded protein response (UPR) induces apoptosis in the trabecular meshwork cells, which then leads to an increase in resistance to aqueous humor outflow, elevated intraocular pressure (IOP), and, ultimately, glaucoma. Culturing human trabecular meshwork (HTM) cells at a condition facilitating protein folding promotes secretion of mutant myocilin, normalizes cell morphology and reverses cell lethality.
Presentation of the Hypothesis
We speculate that a complete elimination of mutant myocilin expression in trabecular meshwork cells is safe and that gives the possibility of avoiding the POAG phenotype.
Testing the Hypothesis
We propose RNA interference (RNAi) as a gene silencing therapy to eliminate the mutant myocilin proteins in the trabecular meshwork cells, either in a mutation-dependent or mutation-independent way due to the different engineering of the small interfering (si) RNA.
Implications of the Hypothesis
The RNAi strategy can reverse the pathological process of trabecular meshwork cells and thus treat the POAG caused by myocilin gene mutation. This strategy can also be applicable to many protein-misfolding diseases caused by gain-of-function mutant proteins.
Glaucoma is a group of progressive optic neuropathies that have in common a slow progressive degeneration of retinal ganglion cells and their axons, resulting in a distinct appearance of the optic disc and a concomitant pattern of visual loss. Without adequate treatment, glaucoma can progress to irreversible visual disability and eventual blindness . Of the many types of glaucoma, primary open angle glaucoma (POAG) is perhaps the most common, particularly in populations of African ancestry and European [2–4]. In most cases of POAG, increased resistance to the outflow of aqueous humor results in a rise in intraocular pressure (IOP), which eventually leads to loss of retinal ganglion cells. Though Increased IOP has been proven to be the only treatable risk factor for glaucoma, the biological basis of the disease is not yet fully understood. This may underlies that the present treatment of POAG directed at lowering IOP does not seem to halt all cases of progression [7–10]. To date, six loci (GLC1A-E) have been linked to POAG alone. Among them, the gene MYOC encoding myocilin has been identified as harboring causal mutations, which are responsible for 3-4% adult-onset POAG cases . This warrants the gene therapy which holds the promise for curing the disease. Current investigations of gene therapy mainly focus on the transfer and expression of genes encoding IOP-lowering, neuroprotective gene products, and/or, wound healing inhibitors, but do not really emphasize a specific elimination of the causal mutant proteins. Here we propose RNA interference (RNAi) as gene silencing therapy for complete elimination of mutant myocilin from human trabecular meshwork (HTM) cells.
Presentation of Hypothesis
The human myocilin gene encodes a 504 amino acid glycoprotein expressed extra- or intracellularly in almost every ocular tissue[13, 14] but predominantly in the trabecular meshwork which is a tissue provides major resistance to the aqueous humor outflow pathway, and the tissue involved in elevated IOP associated with glaucoma. However, MYOC-null individuals (no matter mice  or human beings [17, 18] have normal eyes and intraocular pressure. These individuals are both viable and fertile as well [16–18]. Overexpression of wild type (WT) MYOC in transgenic mice does not lead to any glaucomatous phenotype[19, 20]. All these facts suggest that haploinsufficiency of MYOC is not a critical mechanism in the pathogenesis of POAG [16–20].
A variety of recent studies show that the mutant myocilin acts in the HTM cells by gain of function[16, 21–27]. It was observed that, in culture media, very little to no mutant myocilin associated with the development of glaucoma was secreted out of the HTM cells, while WT and polymorphism variant myocilin were secreted normally. Further investigations found that the disease-causing myocilin mutants were actually misfolded, were highly aggregation-prone and accumulated in large aggregates or formed heteromeric complexes with WT myocilin in the endoplasmic reticulum (ER)[5, 22, 24, 28]. The ER is responsible for the synthesis, modification and delivery of correctly folded proteins to their proper target sites. Increased expression of mutant, folding-incompetent proteins causes ER stress and an ER stress response, called the unfolded protein response(UPR). The UPR is an adaptive mechanism to return the ER to its normal physiological state by upregulating the ER folding capacity and down-regulating the biosynthetic load of the ER. When the UPR does not remedy the stress situation, apoptosis is initiated in higher eukaryotic organisms, presumably to eliminate unhealthy cells . In the case of MYOC-associated POAG, the aggregates induced the unfolded protein response proteins BiP and phosphorylated endoplasmic reticulum-localized eukaryotic initiation factor-2_ kinase (PERK) with the subsequent activation of caspases 12 and 3 and expression of C/EBP homologous protein (CHOP)/GADD153, leading to abnormal HTM cell morphology and cell apoptosis[24, 28]. The progressive loss of HTM cells due to apoptosis should accordingly diminish the phagocytotic capacity of the remaining TM cell population to clean the outflow drainage and eventually results in humor outflow resistance and elevated IOP. This is consist with the electron microscopic findings from biopsies of POAG patients showing a reduction of TM cells as well as thickened trabeculae and accumulation of sheath-derived plaques [30–33].
Since the mutant myocilin induces ER stress and eventually leads to the apoptosis of HTM cells and hence the pathogenesis of Myoc- associated glaucoma, a complete elimination of mutant myocilin in HTM cells may disrupt or even partly reverse the disease. In support of this proposal are two major previous investigation findings: (1) Culturing HTM cells at a condition facilitating protein folding promotes secretion of mutant myocilin, normalizes cell morphology and reverses cell lethality, and (2) MYOC-null individuals have no glaucomatous phenotype and are both viable and fertile as well [16–18].
Testing the Hypothesis
To eliminate the mutant myocilin in HTM cells, RNAi can be used as a powerful gene silencing method [34–37], either in a mutation-dependent  or a mutation-independent way . In mutation dependent RNAi, a customized double-stranded small interfering (si) RNA targeting a mutant sequence is synthesized and conducted by a plasmid to the HTM cell expressing the very mutant myocilin. The siRNA can be engineered specifically to suppress the mutant alleles differing from WT alleles as little as only a single nucleotide, so that the WT myocilin can express normally in the heterozygotes without being insulted. However, myocilin-associated POAG is intragenic heterogeneous  and customized siRNA inhibition targeting large numbers of individual mutations would be costly. A more economical approach of mutation-independent silencing will avoid this drawback. In this approach, siRNA complementary to the untranslated regions (UTRs) of the target mRNA is conducted to the HTM cell and hence both the WT and mutant alleles would be suppressed. Moreover, a replacement WT myocilin gene with modified UTRs that is sparing from the suppression can be generated and conducted into the cell, allowing the expression of WT alleles while suppressing that of the mutant ones simultaneously. In the case of MYOC- associated POAG, the insertion of the replacement WT myocilin gene may be unnecessary for suppression of myocilin gene totally limited to HTM cells might not lead to pathological phenotypes. If such a suppression without inserting the replacement WT gene is safe, the mutation-independent strategy would probably be the best choice among the above proposals.
Implications of the Hypothesis
In this article, we propose RNAi as a gene silencing therapy for the MYOC-associated POAG. It has been demonstrated by abundant researches [5, 22, 24, 28] that mutant myocilin proteins are insufficiently folded and accumulate in the ER, inducing UPR with subsequently activated cell apoptosis. We hypothesize that if these mutant proteins are suppressed by siRNA mediated RNAi, the cell lesion would be reversed. To the best of our knowledge, our idea of treating POAG by inhibiting the disease causing gene has not been stated before. Those investigated strategies of gene therapy for glaucoma do not aim at the disease causing mutants, but focus on inducing genes compensating for the defects , which are actually the modifications of contemporary treatments at the gene level. Compared with this, the RNAi strategy we propose here is more specific to the etiological factor and would likely to be more effective. Shinohara et al proposed a hypothesis of treating the retinitis pigmentosa (RP) by silencing the mutant rhodopsin in a allele-specific way. However, since MYOC-null individuals have been reported to be healthy, we suspect that totally suppressing the myocilin without inserting a replacement WT myocilin to HTM cells would be safe and economically feasible.
ER retention of mutant proteins has been implicated in the pathogenesis of many ER storage diseases other than POAG, including some inherited neurodegenerative disorders like Alzheimer's disease . The RNAi strategy aiming at eliminating the misfolded mutant proteins can also be applied to these disorders. Problems to be solved are the safety and efficiency of RNAi. A highly efficient siRNA should be chosen from a variety of candidates and the side effects should be observed with caution by a series of investigations before it can be carried out clinically.
Weinreb RN, Khaw PT: Primary open-angle glaucoma. Lancet. 2004, 363: 1711-1720. 10.1016/S0140-6736(04)16257-0.
Rahmani B, Tielsch JM, Katz J, Gottsch J, Quigley H, Javitt J, Sommer A: The cause-specific prevalence of visual impairment in an urban population. The Baltimore Eye Survey. Ophthalmology. 1996, 103: 1721-1726.
Quigley HA, Vitale S: Models of open-angle glaucoma prevalence and incidence in the United States. Invest Ophthalmol Vis Sci. 1997, 38: 83-91.
Rudnicka AR, Mt-Isa S, Owen CG, Cook DG, Ashby D: Variations in primary open-angle glaucoma prevalence by age, gender, and race: a Bayesian meta-analysis. Invest Ophthalmol Vis Sci. 2006, 47: 4254-4261. 10.1167/iovs.06-0299.
Liu Y, Vollrath D: Reversal of mutant myocilin non-secretion and cell killing: implications for glaucoma. Hum Mol Genet. 2004, 13: 1193-1204. 10.1093/hmg/ddh128.
American Academy of Ophthalmology PPPC, Glaucoma Panel: Preferred practice pattern: primary open-angle glaucoma. 2000, San Francisco, Calif: American Academy of Ophthalmology
Kass MA, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JL, Miller JP, Parrish RK, Wilson MR, Gordon MO: The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002, 120: 701-713.
Heijl A, Leske MC, Bengtsson B, Hyman L, Hussein M: Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002, 120: 1268-1279.
Lichter PR, Musch DC, Gillespie BW, Guire KE, Janz NK, Wren PA, Mills RP: Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery. Ophthalmology. 2001, 108: 1943-1953. 10.1016/S0161-6420(01)00873-9.
The Advanced Glaucoma Intervention Study (AGIS): 4. Comparison of treatment outcomes within race. Seven-year results. Ophthalmology. 1998, 105: 1146-1164. 10.1016/S0161-6420(98)97013-0.
Fingert JH, Héon E, Liebmann JM, Yamamoto T, Craig JE, Rait J, Kawase K, Hoh ST, Buys YM, Dickinson J, Hockey RR, Williams-Lyn D, Trope G, Kitazawa Y, Ritch R, Mackey DA, Alward WL, Sheffield VC, Stone EM: Analysis of myocilin mutations in 1703 glaucoma patients from five different populations. Hum Mol Genet. 1999, 8: 899-905. 10.1093/hmg/8.5.899.
Borras T, Brandt CR, Nickells R, Ritch R: Gene therapy for glaucoma: treating a multifaceted, chronic disease. Invest Ophthalmol Vis Sci. 2002, 43: 2513-2518.
Karali A, Russell P, Stefani FH, Tamm ER: Localization of myocilin/trabecular meshwork--inducible glucocorticoid response protein in the human eye. Invest Ophthalmol Vis Sci. 2000, 41: 729-740.
Swiderski RE, Ross JL, Fingert JH, Clark AF, Alward WL, Stone EM, Sheffield VC: Localization of MYOC transcripts in human eye and optic nerve by in situ hybridization. Invest Ophthalmol Vis Sci. 2000, 41: 3420-3428.
Adam MF, Belmouden A, Binisti P, Brézin AP, Valtot F, Béchetoille A, Dascotte JC, Copin B, Gomez L, Chaventré A, Bach JF, Garchon HJ: Recurrent mutations in a single exon encoding the evolutionarily conserved olfactomedin-homology domain of TIGR in familial open-angle glaucoma. Hum Mol Genet. 1997, 6: 2091-2097. 10.1093/hmg/6.12.2091.
Kim BS, Savinova OV, Reedy MV, Martin J, Lun Y, Gan L, Smith RS, Tomarev SI, John SW, Johnson RL: Targeted Disruption of the Myocilin Gene (Myoc) Suggests that Human Glaucoma-Causing Mutations Are Gain of Function. Mol Cell Biol. 2001, 21: 7707-7713. 10.1128/MCB.21.22.7707-7713.2001.
Pang CP, Leung YF, Fan B, Baum L, Tong WC, Lee WS, Chua JK, Fan DS, Liu Y, Lam DS: TIGR/MYOC gene sequence alterations in individuals with and without primary open-angle glaucoma. Invest Ophthalmol Vis Sci. 2002, 43: 3231-3235.
Wiggs JL, Vollrath D: Molecular and clinical evaluation of a patient hemizygous for TIGR/MYOC. Arch Ophthalmol. 2001, 119: 1674-1678.
Gould DB, Miceli-Libby L, Savinova OV, Torrado M, Tomarev SI, Smith RS, John SW: Genetically increasing Myoc expression supports a necessary pathologic role of abnormal proteins in glaucoma. Mol Cell Biol. 2004, 24: 9019-9025. 10.1128/MCB.24.20.9019-9025.2004.
Zillig M, Wurm A, Grehn FJ, Russell P, Tamm ER: Overexpression and properties of wild-type and Tyr437His mutated myocilin in the eyes of transgenic mice. Invest Ophthalmol Vis Sci. 2005, 46: 223-234. 10.1167/iovs.04-0988.
Caballero M, Rowlette LL, Borras T: Altered secretion of a TIGR/MYOC mutant lacking the olfactomedin domain. Biochim Biophys Acta. 2000, 1502: 447-460.
Caballero M, Borras T: Inefficient processing of an olfactomedin-deficient myocilin mutant: potential physiological relevance to glaucoma. Biochem Biophys Res Commun. 2001, 282: 662-670. 10.1006/bbrc.2001.4624.
Sohn S, Hur W, Joe MK, Kim JH, Lee ZW, Ha KS, Kee C: Expression of wild-type and truncated myocilins in trabecular meshwork cells: their subcellular localizations and cytotoxicities. Invest Ophthalmol Vis Sci. 2002, 43: 3680-3685.
Joe MK, Sohn S, Hur W, Moon Y, Choi YR, Kee C: Accumulation of mutant myocilins in ER leads to ER stress and potential cytotoxicity in human trabecular meshwork cells. Biochem Biophys Res Commun. 2003, 312: 592-600. 10.1016/j.bbrc.2003.10.162.
Gobeil S, Rodrigue MA, Moisan S, Nguyen TD, Polansky JR, Morissette J, Raymond V: Intracellular sequestration of hetero-oligomers formed by wild-type and glaucoma-causing myocilin mutants. Invest Ophthalmol Vis Sci. 2004, 45: 3560-3567. 10.1167/iovs.04-0300.
Jacobson N, Andrews M, Shepard AR, Nishimura D, Searby C, Fingert JH, Hageman G, Mullins R, Davidson BL, Kwon YH, Alward WL, Stone EM, Clark AF, Sheffield VC: Non-secretion of mutant proteins of the glaucoma gene myocilin in cultured trabecular meshwork cells and in aqueous humor. Hum Mol Genet. 2001, 10: 117-125. 10.1093/hmg/10.2.117.
Gobeil S, Letartre L, Raymond V: Functional analysis of the glaucoma-causing TIGR/myocilin protein: integrity of amino-terminal coiled-coil regions and olfactomedin homology domain is essential for extracellular adhesion and secretion. Exp Eye Res. 2006, 82: 1017-1029. 10.1016/j.exer.2005.11.002.
Yam GH, Gaplovska-Kysela K, Zuber C, Roth J: Aggregated myocilin induces russell bodies and causes apoptosis: implications for the pathogenesis of myocilin-caused primary open-angle glaucoma. Am J Pathol. 2007, 170: 100-109. 10.2353/ajpath.2007.060806.
Schroder M, Kaufman RJ: ER stress and the unfolded protein response. Mutat Res. 2005, 569: 29-63.
Alvarado J, Murphy C, Juster R: Trabecular meshwork cellularity in primary open-angle glaucoma and nonglaucomatous normals. Ophthalmology. 1984, 91: 564-579.
Alvarado JA, Yun AJ, Murphy CG: Juxtacanalicular tissue in primary open angle glaucoma and in nonglaucomatous normals. Arch Ophthalmol. 1986, 104: 1517-1528.
Lutjen-Drecoll E, Shimizu T, Rohrbach M, Rohen JW: Quantitative analysis of 'plaque material' in the inner- and outer wall of Schlemm's canal in normal- and glaucomatous eyes. Exp Eye Res. 1986, 42: 443-455. 10.1016/0014-4835(86)90004-7.
Rohen JW, Lutjen-Drecoll E, Flugel C, Meyer M, Grierson I: Ultrastructure of the trabecular meshwork in untreated cases of primary open-angle glaucoma (POAG). Exp Eye Res. 1993, 56: 683-692. 10.1006/exer.1993.1085.
Novina CD, Sharp PA: The RNAi revolution. Nature. 2004, 430: 161-164. 10.1038/430161a.
Sontheimer EJ, Carthew RW: Molecular biology. Argonaute journeys into the heart of RISC. Science. 2004, 305: 1409-1410. 10.1126/science.1103076.
Caplen NJ: Gene therapy progress and prospects. Downregulating gene expression: the impact of RNA interference. Gene Ther. 2004, 11: 1241-1248. 10.1038/sj.gt.3302324.
Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T: Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature. 2001, 411: 494-498. 10.1038/35078107.
Miller VM, Xia H, Marrs GL, Gouvion CM, Lee G, Davidson BL, Paulson HL: Allele-specific silencing of dominant disease genes. Proc Natl Acad Sci USA. 2003, 100: 7195-7200. 10.1073/pnas.1231012100.
Kiang AS, Palfi A, Ader M, Kenna PF, Millington-Ward S, Clark G, Kennan A, O'reilly M, Tam LC, Aherne A, McNally N, Humphries P, Farrar GJ: Toward a gene therapy for dominant disease: validation of an RNA interference-based mutation-independent approach. Mol Ther. 2005, 12: 555-561. 10.1016/j.ymthe.2005.03.028.
Fingert JH, Stone EM, Sheffield VC, Alward WL: Myocilin glaucoma. Surv Ophthalmol. 2002, 47: 547-561. 10.1016/S0039-6257(02)00353-3.
Shinohara T, Mulhern ML, Madson CJ: Silencing gene therapy for mutant membrane, secretory, and lipid proteins in retinitis pigmentosa (RP). Med Hypotheses. 2008, 70: 378-380. 10.1016/j.mehy.2007.04.041.
The authors declare that they have no competing interests.
ML conceived the hypothesis and drafted the manuscript; JX conceived the hypothesis and gave modifications of the manuscript; XC involved in drafting the manuscript; XS revised the manuscript critically and gave final approval of the version to be published